TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 years or older~* angiopathic or angioneuropathic critical limb ischemia (at least Wagner-Armstrong stadium II)~* participation in the August-1 Register~* revascularization not possible or residual ischemia after revascularization~* persisting ulcerations despite antibiosis, adjustment of blood glucose levels and debridement~* expected further hospitalization for at least 3 weeks (pressure relief and antibiosis)~* fibrinogen \>= 4g/l~* signed informed consent~Exclusion Criteria:~* life expectancy \< 1 year~* prior major amputation~* planned major amputation~* prior therapy of the current episode of diabetic foot syndrome with urokinase (except in cases of revascularization when the duration between the intervention and randomization must not exceed 7 days)~* mechanical heart valve substitute~* cerebral event with CT-detectable changes in the last 3 months~* non-remediated proliferation retinopathy~* uncontrolled hypertension (systolic \>180 mmg, diastolic \>100 mmHg)~* hemorrhagic diathesis (spontaneous quick \< 50%, spontaneous PTT \> 40 s, thrombocytes \< 100 Gpt/l)~* gastrointestinal bleeding or ulcers in the last 4 weeks~* prior reverse bypass operation~* contraindications against therapy with urokinase acc. to the SMPc~* concurrent participation in another clinical trial~* insufficient compliance~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard therapy (Type: NO_INTERVENTION): patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
- urokinase (Type: ACTIVE_COMPARATOR): patients receiving urokinase short infusions in addition to standard therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraocular Lens (IOL) Calculation Improvement

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* older 18~* clear cornea~* cataract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cataract patients (Type: None): cataract patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia) and has failed one or two prior standard induction attempts. Failure is defined as:~* ≥ 30% bone marrow blasts with at least 20% cellularity at mid-cycle bone marrow biopsy or residual AML on subsequent\~ day 28 bone marrow biopsy by morphology, flow, PCR or FISH~* Patients enrolling after only 1 failed induction attempt must meet at least one of the following additional eligibility criteria of high risk: ≥ 60 years of age adverse cytogenetics or molecular characteristics~* AML that progressed out of myelodysplastic syndrome (MDS) is eligible if the patient did not receive treatment directed at the MDS~* HLA-haploidentical related donor (aged 12 to 70 years)~* ≥ 18, but \< 75 years of age~* Karnofsky performance status ≥ 60%~* Adequate organ function within 14 days of study registration (30 days for pulmonary and cardiac) as defined in section 4.5~* Ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to the NK cell infusion (excluding preparative regimen pre-meds)~* No prior hematopoietic transplant~* Not pregnant or lactating~* Sexually active females of childbearing potential and males with partners of child bearing potential must agree to use birth control~Exclusion Criteria:~* Pregnant or lactating as the treatments used in this study includes drugs that are FDA Pregnancy Category D.~* Acute leukemias of ambiguous lineage~* AML that transformed from previously treated myelodysplastic syndromes~* Prior hematopoietic transplant~* New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that has not been cleared by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections)~* Uncontrolled bacterial, fungal, or viral infections including HIV - chronic asymptomatic viral hepatitis is allowed~* Known hypersensitivity to one or more of the study agents used

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single-arm trial (Type: OTHER): Multi-center, open-label, single-arm, phase I/II clinical trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patients aged 55 and above~Exclusion Criteria:~* Patient who takes antioxidant treatment will be asked to stop, or can't be included in the study~* Patients who had a CVD incident (MI, Stroke, TIA), Unstable angina pectoris, Uncontrolled HTN, will have to wait a month after stabilization to be included in the study~* Allergy to Vitamin E

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Coagulation Profiles Between Zoely and Minidoz: RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Woman age 19-40 yr~* Normal uterus and both adnexae~* BMI \< 28.5 kg/m2~* Require contraception with COCs~Exclusion Criteria:~* Pregnancy~* Postartum period within 6 wk~* Smoking~* BP ≥ 140/90 mmHg~* Contraindication to COCs : VTE, cerebrovascular disease, cardiovascular disease, migraine with aura, hepatitis, undiagnosed abnormal uterine bleeding, CA breast, DM with DN/DR~* use of liver-enzyme-inducing drugs, drugs affecting the haemostatic system~* Use contraceptive steroids within 3 months

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Zoely (Type: ACTIVE_COMPARATOR): Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
- Minidoz (Type: ACTIVE_COMPARATOR): Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA in serum~* AST/ALT greater than the upper limit of normal range~* HVPG \>5 mm Hg~* Non-response or contraindication to a standard course of antiviral therapy~Exclusion Criteria:~* Active alcoholism~* HIV infection~* Serum creatinine \>1.2 mg/dl, hemoglobin \<11 g/dl, hemolysis, symptomatic ischemic heart disease or cerebrovascular disease~* Decompensated chronic liver disease~* Pregnancy~* Hypersensitivity to the drugs of the study~* Severe concomitant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ribavirin (Type: EXPERIMENTAL): Ribavirin 1000-1200 mg qd
- Colchicine (Type: ACTIVE_COMPARATOR): Colchicine 0.5 mg bd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Environment Effect on Six-Minute Walk Test Performance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age above 18 years.~2. Have a diagnosis of congenital Alpha-1 Antitrypsin Deficiency with an allelic combination of ZZ.~3. Have a Forced Expiratory Volume in 1 second (FEV1)\< 50% of predicted and FEV1/forced vital capacity (FVC) \< 70% (Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] stage II, III, or IV).~4. Not currently prescribed Oxygen replacement at a rate of greater than 2 liters.~5. Willing and able to perform two six-minute walk tests.~6. Willing and able to provide written informed consent.~Exclusion Criteria:~1. Subject has had a moderate or severe pulmonary exacerbation during the 4 weeks before the study visit.~2. History of lung transplant.~3. Severe concomitant disease (e.g., congestive heart failure, clinically significant pulmonary fibrosis, malignant disease \[with the exception of skin cancers other than melanoma\], history of acute hypersensitivity pneumonitis reaction, or current chronic hypersensitivity pneumonitis).~4. Unwilling or unable to perform six-minute walk testing.~5. Mentally challenged adult subjects who cannot give independent informed consent.~6. In the opinion of the investigator the subject may have compliance problems with the protocol and the procedures of the protocol.~7. American Thoracic Society listed absolute contraindications to six-minute walk test: unstable angina or myocardial infarction during previous month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- six-minute walk study indoors first (Type: ACTIVE_COMPARATOR): Participants randomized to indoor six-minute walk test first
- six-minute walk study outdoors first (Type: EXPERIMENTAL): Participants randomized to outdoor six-minute walk test first
- six-minute walk study indoors second (Type: ACTIVE_COMPARATOR): Participants randomized to indoor six-minute walk test second
- six-minute walk study outdoors second (Type: EXPERIMENTAL): Participants randomized to outdoor six-minute walk test second

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed consent~* Confirmed COVID-19 (i.e. symptoms + positive test for SARS-CoV-2)~* Male or female, age ≥ 55 years~* At least two of the following additional risk factors:~Age ≥ 70 years Body mass index \> 25 kg/m2 Chronic obstructive pulmonary disease (COPD)\* Diabetes\* Cardiovascular disease\* Corticosteroid use~\*Defined as any disease requiring medical intervention or treatment.~Exclusion Criteria:~* Contraindications to unfractionated heparin or LMWH~* Recent (\<48 hours) or planned spinal or epidural anesthesia or puncture, PCI or thrombolytic therapy within the preceding 24 hours~* Increased risk for bleeding complications~* Pregnant women~* Severe renal impairment (GFR \< 30 mL/min)~* Receiving any antiplatelet therapy (with the exception of low dose (≤100mg) aspirin) or anticoagulant therapy (e.g. VKA, DOAC)~* Patients participating in an interventional study that is outside the purview of TRI sponsored studies.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enoxaparin (Type: EXPERIMENTAL): (40 mg o/d if \< 100 kg, 40 mg b/d if ≥ 100 kg)
- Current standard of care (no enoxaparin) (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be taking sitagliptin phosphate/metformin HCl (JANUMET®) for the treatment of type 2 diabetes mellitus~* Treating physician must agree to provide information regarding the participant's treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants treated with sitagliptin phosphate/metformin HCl (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of an Electronic Monitoring Device on Maintaining a Correct Elevation of Head of Bed for Mechanically-ventilated Patients in Intensive Care Unit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient with invasive mechanical ventilation~* expected mechanical ventilation duration for more than 48h after inclusion~* signature of an informed consent by a relative~* patient affiliated to a social security scheme (beneficiary or assignee)~Exclusion Criteria:~* age\<18 years old~* mechanical ventilation with tracheotomy~* contraindication to semirecumbent position (e.g., spinal cord injury, important sacral bedsore, counterpulsation balloon, femoral cannulation for extracorporeal circulation) or expected indication to another position within the following 48 h after inclusion (e.g., ventral decubitus for hypoxemia pulmonary pathology)~* SAPS II score \> 65 at the admission (moribund patients)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EMD (Inclinomax) then usual care (Type: OTHER): EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h.~Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h.
- usual care then EMD (Inclinomax) (Type: OTHER): Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h.~EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Accuvein in Obese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* obese adults ( BMI equal or greater 35) requiring a venous blood sampling or the placement of a venous peripheral catheter~Exclusion Criteria:~* pregnant woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Accuvein (Type: EXPERIMENTAL): Use of Accuvein to facilitate placement of peripheral intravenous catheters in obese patients
- Routine technique (Type: ACTIVE_COMPARATOR): Routine technique used to insert a peripheral intravenous catheters in obese patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet 1 of the following criteria:~* Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy~  * Stage III or IV disease~ * Clinically assessed with~* Healthy participant~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- fluorine F 18 FEQA + positron emission tomography (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Preliminary Administration of Cyclosporine (Sandimmun ®) on Different Markers of Cardiac Ischaemia Induced by Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient hospitalized for a coronary artery bypass surgery~* Not urgent surgery~* Left ventricular ejection fraction (LVEF)\> 40 %~* 18 years and older~* patient who have sign the informed consent form~* Affiliation to the French Social Security.~Exclusion Criteria:~* Beating heart surgery with or without Cardiopulmonary Bypass~* Patient receiving another surgical gesture combined to the CABG~* Myocardial infarction or vascular cerebral attack less than 30 days~* Previous History of cardiac surgery;~* Renal failure (creatinine \> 200 µmol/l)~* Uncontrolled hypertension~* hyperkaliemy;~* hyperuricemy;~* Acute Coronary Syndrome~* Malignant tumor~* Unchecked infection~* Previous intravenous administration of Sandimmun ®;~* allergy to ciclosporin, ethyl alcohol, castor oil or nitrogen~* Pregnant Woman, parturient without contraception, or breast-feeding~* Age \< 18 years~* Patient who have not signed the form of consent;~* Patient Under guardianship or being the object of a legal protective measure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cyclosporin (Type: ACTIVE_COMPARATOR): Intravenous cyclosporin injection.
- Pacebo (Type: PLACEBO_COMPARATOR): Intravenous injection of NaCl solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Closure After Total Shoulder Arthroplasty: Prineo vs Dermabond

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Total shoulder arthroplasty~* Reverse total shoulder arthroplasty~* Age 18-100~* Single Surgeon~Exclusion Criteria:~* Previous shoulder surgery~* Known wound healing complications~* DM, chronic steroid use, vascular insufficiency, morbid obesity (BMI\>40), ESRD, family hx of pathologic scars~* Patients on blood thinners (ASA 81mg ok)~* Connective tissue disease~* Allergy to skin adhesive~* Mentally unable to complete questionnaires~* Previous wound over planned incision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- 2-Octyl Cyanoacrylate and mesh (Type: EXPERIMENTAL): The wound will be closed with 2-Octyl Cyanoacrylate and a mesh
- 2-Octyl Cyanoacrylate (Type: ACTIVE_COMPARATOR): The wound will be closed with just 2-Octyl Cyanoacrylate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval